Equities analysts expect Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to post $27.26 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Enanta Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $23.97 million and the highest estimate coming in at $30.56 million. Enanta Pharmaceuticals posted sales of $10.42 million during the same quarter last year, which would indicate a positive year over year growth rate of 161.6%. The company is expected to announce its next quarterly earnings results on Wednesday, February 14th.

According to Zacks, analysts expect that Enanta Pharmaceuticals will report full-year sales of $27.26 million for the current year, with estimates ranging from $69.44 million to $97.28 million. For the next fiscal year, analysts anticipate that the firm will post sales of $0.00 per share. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the consensus estimate of $2.13 by ($0.27). The company had revenue of $75.93 million during the quarter, compared to analysts’ expectations of $73.80 million. Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The business’s revenue for the quarter was up 491.3% compared to the same quarter last year. During the same period last year, the company earned ($0.09) earnings per share.

Several analysts have recently commented on ENTA shares. Royal Bank of Canada started coverage on Enanta Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating for the company. JMP Securities increased their price objective on Enanta Pharmaceuticals from $40.00 to $53.00 in a research note on Wednesday, October 4th. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Finally, TheStreet raised Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $46.25.

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded up $1.88 during trading on Friday, hitting $55.83. The stock had a trading volume of 483,235 shares, compared to its average volume of 208,339. The stock has a market capitalization of $1,100.00, a P/E ratio of 61.31 and a beta of 0.64. Enanta Pharmaceuticals has a 12-month low of $25.92 and a 12-month high of $55.85.

Institutional investors and hedge funds have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. increased its position in shares of Enanta Pharmaceuticals by 0.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 53,616 shares of the biotechnology company’s stock valued at $1,930,000 after acquiring an additional 304 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Enanta Pharmaceuticals by 6.9% during the second quarter. Vanguard Group Inc. now owns 847,021 shares of the biotechnology company’s stock valued at $30,475,000 after acquiring an additional 54,856 shares during the last quarter. Louisiana State Employees Retirement System purchased a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $205,000. Dimensional Fund Advisors LP increased its position in shares of Enanta Pharmaceuticals by 34.3% during the second quarter. Dimensional Fund Advisors LP now owns 554,777 shares of the biotechnology company’s stock valued at $19,961,000 after acquiring an additional 141,688 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Enanta Pharmaceuticals by 43.0% during the second quarter. Goldman Sachs Group Inc. now owns 83,704 shares of the biotechnology company’s stock valued at $3,012,000 after acquiring an additional 25,154 shares during the last quarter. 66.97% of the stock is owned by institutional investors.

WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/16/27-26-million-in-sales-expected-for-enanta-pharmaceuticals-inc-enta-this-quarter.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.